9 citations
,
August 2024 in “Australian Prescriber” This review highlights that pharmacotherapy for polycystic ovary syndrome should address individual patient concerns, with metformin beneficial for reducing weight and metabolic risk, and lifestyle modifications also important.
June 2026 in “Quality in Sport” This narrative review found that combined oral contraceptives remain the primary treatment for hirsutism and acne in women with PCOS, but highlighted the need for further research to refine therapeutic options given the variable efficacy and emerging treatments like GLP-1 receptor agonists.
March 2026 in “Anti-Aging Eastern Europe” This review examines current evidence on personalized management strategies for PCOS, but does not present new clinical results; the authors advocate for treatments tailored to predominant symptoms and individual health profiles.
February 2025 in “Journal of Neonatal Surgery” This study explores the role of antidiabetic medications, particularly metformin, GLP-1 receptor agonists, and DPP-4 inhibitors, in managing PCOS, highlighting their combination with hormonal therapies and lifestyle interventions for a comprehensive treatment approach.
April 2024 in “Canadian Women s Health Today” This review suggests that "polycystic ovarian syndrome" is a misleading name, as the disorder involves complex metabolic and reproductive issues beyond ovarian dysfunction and may stem from factors affecting the fetus in utero.